Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1969 1
1972 1
1973 4
1974 1
1975 17
1976 27
1977 59
1978 65
1979 51
1980 47
1981 60
1982 66
1983 87
1984 79
1985 68
1986 85
1987 63
1988 80
1989 91
1990 104
1991 82
1992 95
1993 89
1994 100
1995 110
1996 107
1997 119
1998 137
1999 122
2000 161
2001 174
2002 182
2003 199
2004 212
2005 190
2006 244
2007 197
2008 211
2009 218
2010 245
2011 262
2012 259
2013 263
2014 324
2015 318
2016 330
2017 303
2018 331
2019 304
2020 337
2021 360
2022 332
2023 316
2024 122

Text availability

Article attribute

Article type

Publication date

Search Results

7,731 results

Results by year

Filters applied: . Clear all
Page 1
Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort : A Prospective Observational Cohort Study.
Fuchs A, Kühl JT, Sigvardsen PE, Afzal S, Knudsen AD, Møller MB, de Knegt MC, Sørgaard MH, Nordestgaard BG, Køber LV, Kofoed KF. Fuchs A, et al. Ann Intern Med. 2023 Apr;176(4):433-442. doi: 10.7326/M22-3027. Epub 2023 Mar 28. Ann Intern Med. 2023. PMID: 36972540
OBJECTIVE: To define characteristics of subclinical coronary atherosclerosis associated with the development of myocardial infarction. ...RESULTS: A total of 5114 (54%) persons had no subclinical coronary atherosclerosis, 3483 (36%) had nonobstructive dise …
OBJECTIVE: To define characteristics of subclinical coronary atherosclerosis associated with the development of myocardial inf …
Endothelin: 30 Years From Discovery to Therapy.
Barton M, Yanagisawa M. Barton M, et al. Hypertension. 2019 Dec;74(6):1232-1265. doi: 10.1161/HYPERTENSIONAHA.119.12105. Epub 2019 Nov 4. Hypertension. 2019. PMID: 31679425 Review.
This article reviews the history of the discovery of endothelin and its role in genetics, physiology, and disease. Here, we summarize the main clinical trials using ERAs and discuss the role of endothelin in cardiovascular diseases such as arterial hypertension, preecclamp …
This article reviews the history of the discovery of endothelin and its role in genetics, physiology, and disease. Here, we summarize …
Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial.
Chaitman BR, Cyr DD, Alexander KP, Pracoń R, Bainey KR, Mathew A, Acharya A, Kunichoff DF, Fleg JL, Lopes RD, Sidhu MS, Anthopolos R, Rockhold FW, Stone GW, Maron DJ, Hochman JS, Bangalore S. Chaitman BR, et al. Circ Cardiovasc Interv. 2022 Aug;15(8):e012103. doi: 10.1161/CIRCINTERVENTIONS.122.012103. Epub 2022 Aug 16. Circ Cardiovasc Interv. 2022. PMID: 35973009 Free PMC article. Clinical Trial.
BACKGROUND: ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) reported an initial invasive treatment strategy did not reduce the risk of death or nonfatal myocardial infarction ( …
BACKGROUND: ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney …
FHL5 Controls Vascular Disease-Associated Gene Programs in Smooth Muscle Cells.
Wong D, Auguste G, Lino Cardenas CL, Turner AW, Chen Y, Song Y, Ma L, Perry RN, Aherrahrou R, Kuppusamy M, Yang C, Mosquera JV, Dube CJ, Khan MD, Palmore M, Kalra J, Kavousi M, Peyser PA, Matic L, Hedin U, Manichaikul A, Sonkusare SK, Civelek M, Kovacic JC, Björkegren JLM, Malhotra R, Miller CL. Wong D, et al. Circ Res. 2023 Apr 28;132(9):1144-1161. doi: 10.1161/CIRCRESAHA.122.321692. Epub 2023 Apr 5. Circ Res. 2023. PMID: 37017084
BACKGROUND: Genome-wide association studies have identified hundreds of loci associated with common vascular diseases, such as coronary artery disease, myocardial infarction, and hypertension. However, the lack of mechanistic insights for many GWAS loc …
BACKGROUND: Genome-wide association studies have identified hundreds of loci associated with common vascular diseases, such as coronary …
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.
Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM 3rd, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Pagé P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Généreux P, Crowley A, Dressler O, Serruys PW; EXCEL Trial Investigators. Stone GW, et al. N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562798 Free article. Clinical Trial.
BACKGROUND: Long-term outcomes after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents, as compared with coronary-artery bypass grafting (CABG), in patients with left main coronary artery disease are not clear …
BACKGROUND: Long-term outcomes after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents, as compared with …
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.
Girerd N, Cleland J, Anker SD, Byra W, Lam CSP, Lapolice D, Mehra MR, van Veldhuisen DJ, Bresso E, Lamiral Z, Greenberg B, Zannad F. Girerd N, et al. Sci Rep. 2022 May 20;12(1):8574. doi: 10.1038/s41598-022-12385-0. Sci Rep. 2022. PMID: 35595781 Free PMC article. Clinical Trial.
Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) and sudden cardiac death (SCD). ...
Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events incl …
Melatonin reduces myocardial cell damage in myocardial ischemia/reperfusion rats by inhibiting NLRP3 activation.
Li S, Li X, Xie F, Bai Y, Ma J. Li S, et al. Cell Mol Biol (Noisy-le-grand). 2023 Dec 31;69(15):259-264. doi: 10.14715/cmb/2023.69.15.43. Cell Mol Biol (Noisy-le-grand). 2023. PMID: 38279429
Mel can regulate the function of cardiovascular system and effectively reduce myocardial cell injury, thus playing a role in myocardial protection, but its specific mechanism is unclear. ...Therefore, Mel may improve autophagy and inflammation during myocardial …
Mel can regulate the function of cardiovascular system and effectively reduce myocardial cell injury, thus playing a role in myoca …
Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery.
Landoni G, Lomivorotov VV, Nigro Neto C, Monaco F, Pasyuga VV, Bradic N, Lembo R, Gazivoda G, Likhvantsev VV, Lei C, Lozovskiy A, Di Tomasso N, Bukamal NAR, Silva FS, Bautin AE, Ma J, Crivellari M, Farag AMGA, Uvaliev NS, Carollo C, Pieri M, Kunstýř J, Wang CY, Belletti A, Hajjar LA, Grigoryev EV, Agrò FE, Riha H, El-Tahan MR, Scandroglio AM, Elnakera AM, Baiocchi M, Navalesi P, Shmyrev VA, Severi L, Hegazy MA, Crescenzi G, Ponomarev DN, Brazzi L, Arnoni R, Tarasov DG, Jovic M, Calabrò MG, Bove T, Bellomo R, Zangrillo A; MYRIAD Study Group. Landoni G, et al. N Engl J Med. 2019 Mar 28;380(13):1214-1225. doi: 10.1056/NEJMoa1816476. Epub 2019 Mar 19. N Engl J Med. 2019. PMID: 30888743 Free article. Clinical Trial.
BACKGROUND: Volatile (inhaled) anesthetic agents have cardioprotective effects, which might improve clinical outcomes in patients undergoing coronary-artery bypass grafting (CABG). METHODS: We conducted a pragmatic, multicenter, single-blind, controlled trial at 36 …
BACKGROUND: Volatile (inhaled) anesthetic agents have cardioprotective effects, which might improve clinical outcomes in patients undergoing …
Low-Density Lipoprotein Cholesterol Is Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry.
Mortensen MB, Dzaye O, Bøtker HE, Jensen JM, Maeng M, Bentzon JF, Kanstrup H, Sørensen HT, Leipsic J, Blankstein R, Nasir K, Blaha MJ, Nørgaard BL. Mortensen MB, et al. Circulation. 2023 Apr 4;147(14):1053-1063. doi: 10.1161/CIRCULATIONAHA.122.061010. Epub 2023 Jan 9. Circulation. 2023. PMID: 36621817 Free PMC article.
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is an important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). However, a sizable proportion of middle-aged individuals with elevated LDL-C level have not developed coronary atherosclero …
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is an important causal risk factor for atherosclerotic cardiovascular disease …
Characterizing Mechanisms of Ischemia in Patients With Myocardial Bridges.
Sinha A, Rahman H, Rajani R, Demir OM, Li KamWa M, Morgan H, Ezad SM, Ellis H, Hogan D, Gulati A, Shah AM, Chiribiri A, Webb AJ, Marber M, Perera D. Sinha A, et al. Circ Cardiovasc Interv. 2024 Jan;17(1):e013657. doi: 10.1161/CIRCINTERVENTIONS.123.013657. Epub 2023 Nov 6. Circ Cardiovasc Interv. 2024. PMID: 37929596 Free PMC article.
We sought to determine the substrates for ischemia in patients with angina with nonobstructive coronary arteries and a MB in the left anterior descending artery. ...Epicardial endothelial dysfunction was defined as a reduction in epicardial vessel diam …
We sought to determine the substrates for ischemia in patients with angina with nonobstructive coronary arteries and a MB …
7,731 results